Addendum: Sartan treatment during pregnancy

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 73, Issue 11, 2005, Pages 904-905

  Alwan, Sura ^a,c   Polifka, Janine E ^b   Friedman, Jan M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN; IRBESARTAN; LOSARTAN; TELMISARTAN; VALSARTAN;

ABORTION; ADULT; ANENCEPHALUS; AORTA COARCTATION; CLEFT PALATE; CLINICAL ARTICLE; FACE MALFORMATION; FEMALE; FETUS; FETUS DEATH; GROWTH RETARDATION; HUMAN; HYPERTENSION; LIMB DEFECT; LUNG HYPOPLASIA; NEWBORN; OLIGOHYDRAMNIOS; PATENT DUCTUS ARTERIOSUS; PREGNANCY; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; TERATOGENICITY; TUBULAR DYSFUNCTION;

ABNORMALITIES, DRUG-INDUCED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; FEMALE; FETAL DEATH; HUMANS; PREGNANCY; TERATOGENS;

EID: 28444459196     PISSN: 15420752     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdra.20194     Document Type: Review

References (15)

1. Alwan S, Polifka JE, Friedman JM. 2005. Angtotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 73:123-130.
2. Berkane N, Carlier P, Verstraete L, et al. 2004. Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Res A Clin Mol Teratol 70:547-549.
3. Biswas PN, Wilton LV, Shakir SW. 2002. The safety of valsartan: results of a postmarketing surveillance study on 12,881 patients in England. J Hum Hypertension 16:795-803.
4. Bos-Thompson M, Hillaire-Buys D, Muller F, et al. 2005. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth. Ann Pharmacother 39:157-161.
5. Briggs GG, Nagoette MP. 2001. Fatal fetal outcome with the combined use of valsartan and atenolol. Ann Pharmacother 35:859-861.
6. Chung NA, Lip GYH, Beevers M, Beevers DG. 2001. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 357:1620.
7. Cox RM, Anderson JM, Cox P. 2003. Defective embryogenesis with angiotensin II receptor antagonists in pregnancy. Br J Obstet Gynaecol 110: 1038-1040.
8. Hinsberger A, Wingen A-M, Hoyer PF. 2001. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 357:1620.
9. Lambot M-A, Vermeylen D, Noel J-C. 2001. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 357:1619-1620.
10. Martinovic J, Benachi A, Laurent N, et al. 2001. Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet 358:241-242.
11. Nayar B, Singhal A, Aggarwal-R, Malhotra N. 2003. Losartan induced fetal toxicity. Ind J Pediatr 70:923-924.
12. Pietrement C, Malot L, Santerne B, et al. 2003. Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist. J Perinatol 23:254-255.
13. Saji H, Yamanaka M, Hagiwara A, Ijiri R. 2001. Losartan and fetal toxic effects. Lancet 357:363.
14. Schaefer C. 2003. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol Teratol 67:591-594.
15. Serreau R, Luton D, Macher M, et al. 2005. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. Br J Obstet Gynaecol 112:710-712.